Related Experiment Video
Updated: Jul 16, 2026

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
Published on: February 23, 2024
Chelation therapy for iron overload
1Southern Iron Disorders Center, G-105, 2022 Brookwood Medical Center Drive, Birmingham, AL 35243, USA. ironmd@dnamail.com
Insights
Iron overload causes organ damage, necessitating effective chelation therapy. New oral iron chelators offer improved management options for various iron overload conditions, including anemias and hemochromatosis.
Area of Science:
- Hematology
- Pharmacology
- Internal Medicine
Background:
- Iron overload leads to significant organ damage in the heart, liver, and endocrine glands.
- Limited physiological mechanisms exist for iron excretion, making therapeutic intervention crucial.
Purpose of the Study:
- To review current and emerging iron chelation therapies for managing iron overload.
- To discuss therapeutic alternatives for patients with hereditary anemias and hemochromatosis.
Main Methods:
- Review of licensed iron chelation drugs (parenteral and oral).
- Assessment of ongoing clinical investigations for novel oral chelators.
- Analysis of therapeutic strategies for diverse iron overload etiologies.
Main Results:
- Three licensed iron chelation drugs are available: one parenteral and two oral.
- Development and investigation of additional oral chelators are expanding treatment options.
- Chelation therapy presents alternatives to phlebotomy for specific patient groups.
Conclusions:
- Effective iron chelation is vital for preventing organ damage in iron overload disorders.
- Emerging oral chelators enhance management strategies for beta-thalassemia major, sickle cell disease, and hemochromatosis.
- Therapeutic advancements provide crucial alternatives for patients with various iron overload conditions.
Abstract:
Iron overload is characterized by excessive iron deposition and consequent injury and dysfunction of the heart, liver, anterior pituitary, pancreas, and joints. Because physiologic mechanisms to excrete iron are very limited, patients with iron overload and its complications need safe, effective therapy that is compatible with their coexisting medical conditions. The availability of three licensed iron chelation drugs (one parenteral, two oral) and the development and clinical investigation of other oral chelators represent new opportunities to prevent or manage iron overload in patients with heritable types of severe anemia, such as beta-thalassemia major and sickle cell disease, and for the formulation of alternatives to phlebotomy therapy for patients with iron overload associated with the HFE gene and other adult age-of-onset types of hemochromatosis, African iron overload, and African-American iron overload.
More Related Videos
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
11:04Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
Published on: September 7, 2019
Related Concept Videos
Antiprotozoal Agents
Extraction: Advanced Methods
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Complexation Equilibria: The Chelate Effect
Pharmaceutical Poisoning: Treatment Strategies
Prevention of Further Absorption of Poison